A World Without Infectious Disease

A new era

We are developing a broad portfolio of product candidates that are designed to combat serious, global infectious diseases in entirely new ways, creating medicines that will have a meaningful impact on people around the world.

Given the global impact of infectious diseases, we are committed to developing cost-effective treatments that can be delivered at scale.

HBV

VIR-2218 + PEG-IFN-⍺
(Treatment)

Indication:
siRNA
Phase:
Phase 2,66%
Collaboration:
Alnylam

VIR-3434 ± VIR-2218 ± PEG-IFN-⍺1
(Treatment)

Indication:
siRNA/Antibody
Phase:
Phase 2,66%
Collaboration:
Alnylam

VIR-2218 + BRII-179
(Treatment)

Indication:
siRNA
Phase:
Phase 2,66%
Collaboration:
Alnylam / Brii Bio

VIR-2218 + TLR82 + PD-13
(Treatment)

Indication:
siRNA
Phase:
Phase 2,66%
Collaboration:
Alnylam / Gilead

HDV

VIR-2218 + VIR-3434
(Treatment)

Indication:
siRNA/Antibody
Phase:
Phase 2,66%
Collaboration:
Alnylam

Influenza A

VIR-2482
(Prophylaxis)

Indication:
Antibody
Phase:
Phase 2,66%
Collaboration:

COVID-19

Sotrovimab
(Treatment – Early)

Indication:
Antibody
Phase:
Authorized,66%
Collaboration:
GlaxoSmithKline

Sotrovimab
(Treatment – Hospitalized)

Indication:
Antibody
Phase:
Phase 3,50%
Collaboration:
GlaxoSmithKline

Sotrovimab
(Prophylaxis)

Indication:
Antibody
Phase:
Phase 3,50%
Collaboration:
GlaxoSmithKline

HIV

VIR-1111*
(Prophylaxis)

Indication:
T Cell
Phase:
Phase 1,66%
Collaboration:
Bill and Melinda Gates Foundation

VIR-1388
(Prophylaxis)

Indication:
T Cell
Phase:
Pre-clinical,66%
Collaboration:
Bill and Melinda Gates Foundation


1: MARCH trial (Part B), PREVAIL platform trial (THRIVE/STRIVE sub-protocols)
2: GS-9688
3: nivolumab
: sotrovimab for early treatment by IV currently has marketing approval, temporary authorization or emergency use authorization in >40 countries. In April 2022, the FDA deauthorized sotrovimab‘s use in all US regions.
*Vaccine designed to establish proof of concept in Phase (Ph) 1 clinical trial to determine whether unique immune response observed in non-human primates can be replicated in humans; ultimately, any candidates we advance as a potential HIV vaccine will require modifications to VIR-1111 before further clinical development.

Our Focus

Chronic and acute infections impact hundreds of millions of people every year.

We are taking aim at some of the world’s largest and most serious infectious diseases, infections that are evasive, challenging, or insufficiently addressed by current approaches including COVID-19, hepatitis B and hepatitis D, influenza A and HIV.

Collaborations to advance our technologies and enable global access

We are collaborating with leading companies and organizations to advance our innovative technologies and to enable global access to our future medicines, including:

gsk logo

alnylam logo

BriiBio logo

bill and melinda gates logo

Institute for Research in Biomedicine logo

OHSU logo